PerkinElmer COVID-19 Enterprise Solution –
Helping You Reach the New Normal

Request more Information About Your Passport to The New Normal

As the pandemic evolves, people are adapting to the new normal. The World Travel and Tourism Council calculated the restrictions on travel caused by the pandemic would take $4.7 trillion out of global domestic product in 20201. Airlines, hotels, cruise lines and other such organizations need to recover wisely, and quickly. Companies want to know if it is safe to allow employees and visitors to access their site. Educational institutions want to know if their students are safe in the campus.

PerkinElmer has established the COVID-19 Enterprise Solution to help you:

  • Create a safe operating environment for establishments
  • Protect employees and students

  • Meet evolving travel requirements


PerkinElmer’s COVID-19 Enterprise Solution will allow organizations to promptly identify individuals who are infected with SARS-CoV-2 and pose a risk to others. Organizations will simply have to tell us who, where and when – we will do the rest.

It will be a few years before vaccines become the perfect solution to this pandemic. A negative SARS-CoV-2 test result is expected to be critical for the foreseeable future.

PerkinElmer’s COVID-19 Enterprise Solution Workflow


COVID-19 Enterprise Solution Fast Implementation

Fast Implementation:

With a broad network of internal and external COVID-19 testing facilities and HIPAA compliant end-user interface options, PerkinElmer can deliver testing solutions that can be implemented rapidly and effectively. We can help you get your business or organization back on its feet now.

COVID-19 Enterprise Solution Full Service

Full Service:

PerkinElmer is a one-stop shop for your organization’s testing needs. We are a vertically integrated COVID-19 testing solution provider, uniquely positioned to handle the end-to-end process from sample collection to secure reporting. PerkinElmer owns one of the strongest COVID-19 supply chains by virtue of our redundant manufacturing lines in multiple continents.

PerkinElmer New Coronavirus (2019-nCoV) Nucleic Acid Detection Kit

High-quality Tests:

PerkinElmer manufactures the most sensitive commercially available RT-PCR COVID-19 test kit2, *. This kit is authorized for testing individuals who are not showing symptoms of COVID-19. PerkinElmer also manufactures a sensitive rapid antigen test** based on lateral flow technology.

FDA’s Performance Comparison of Nucleic Acid-based SARS-CoV-2 Assays

The FDA developed an experiment to precisely compare the analytical sensitivity of the nucleic acid-based SARS-CoV-2 assays which have received EUA authorization and published a comparative performance analysis. This assessment used the FDA SARS-CoV-2 Reference Panel which allowed a consistent determination of the relative sensitivity of these tests and their cross-reactivity with the MERS-CoV virus. As can be seen in Table 2 on the FDA website, the PerkinElmer New Coronavirus Nucleic Acid Detection Kit had the lowest LOD of the commercially available kits tested.


  1. World Travel & Tourism Council, November 2020 Projections, Global Recovery Scenarios 2020 Updates. Nov. 2020.
  2. Lowest LOD and most sensitive reflect a comparison of analytical sensitivity between Emergency Use Authorized COVID test kits as reported in FDA SARS-CoV-2 Reference Panel on January, 13, 2021.
Request more Information About Your Passport to The New Normal

*Product sold in the U.S. is for emergency use authorization only.

**Product may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.